Skip to content
    IDXX
    Earnings call· Dec 2024(Q4 FY24)

    IDEXX LABORATORIES INC /DE IDXX

    Feb 3, 2025 Source

    Executive summary

    IDEXX Q4 FY24 — Strong Q4 Performance Driven by Innovation and International Growth Amidst US Clinical Visit Headwinds

    IDEXX delivered a solid Q4 FY24, exceeding expectations with 6% organic revenue growth, driven by strong international performance and new product launches like inVue Dx and Cancer Dx. Despite persistent declines in U.S. clinical visits, the company achieved a significant growth premium, supported by innovation and commercial execution. Management is focused on leveraging its robust pipeline and expanding global footprint to drive future growth, while navigating macroeconomic pressures.

    Highlights

    5

    • Q4 organic revenue increased 6%, ahead of expectations.

    • CAG Diagnostic recurring revenues grew 7% organically in Q4.

    • Full year 2024 comparable EPS increased 12% to $10.67 per share.

    • Global premium instrument installed base grew 9% in 2024, with 18,500 placements.

    • International CAG Diagnostic recurring revenue grew 12% in Q4.

    Concerns

    4

    • U.S. same-store clinical visit levels declined nearly 3% in Q4 and 2% for the full year 2024.

    • Q4 premium instrument placements were down 12% from prior year levels.

    • Rapid assay revenue was flat organically in Q4, partly due to a 4% headwind from the pancreatic lipase slide.

    • Foreign exchange had a $0.03 per share EPS headwind in Q4 and $0.05 for the full year.

    Guidance & targets

    21
    CategoryTargetConfidence
    Full-year 2025 Revenue (reported)
    $4.055B-$4.170B
    high materiality
    High
    Full-year 2025 Revenue (organic)
    6%-9%
    high materiality
    High
    Full-year 2025 CAG Diagnostic recurring revenue organic growth
    5%-8%
    high materiality
    High
    Full-year 2025 Operating Margin (reported)
    31%-31.5%
    high materiality
    High
    Full-year 2025 Operating Margin Improvement (comparable)
    30-80 basis points
    high materiality
    High
    Full-year 2025 EPS
    $11.74-$12.24 per share
    high materiality
    High
    Full-year 2025 EPS Growth (comparable)
    8%-12%
    high materiality
    High
    Full-year 2025 Free Cash Flow conversion
    85%-90%
    medium materiality
    High
    Full-year 2025 Capital spending
    ~$160M
    medium materiality
    High
    Full-year 2025 Share repurchases
    $1.5B
    high materiality
    High
    Q1 2025 Organic Revenue Growth
    4%-6%
    medium materiality
    High
    Q1 2025 CAG Diagnostic recurring revenue organic growth
    4%-6%
    medium materiality
    High
    Q1 2025 Reported Operating Margins
    30.2%-30.6%
    medium materiality
    High
    Full-year 2025 FX impact on revenue growth
    2% negative
    low materiality
    High
    Full-year 2025 FX impact on EPS
    $0.21 headwind
    low materiality
    High
    Full-year 2025 Global net price realization
    4%-4.5%
    medium materiality
    High
    Full-year 2025 Volume gains
    ~2%
    medium materiality
    High
    Full-year 2025 U.S. same-store clinical visit growth
    similar rate of decline seen in 2024
    high materiality
    High
    Full-year 2025 IDEXX inVue Dx instrument revenue
    ~$50M
    medium materiality
    High
    Full-year 2025 IDEXX inVue Dx placements
    4,500
    medium materiality
    High
    Full-year 2025 Net interest expense
    $42M
    low materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    CAG
    CAG performance was supported by strong global growth in consumable revenues and solid new business gains, despite pressure on U.S. same-store clinical visit levels.
    Diagnostic recurring revenue organic growth: 7% (Q4)U.S. Diagnostic recurring revenue organic growth: 4% (Q4, net of 1% selling days impact)International Diagnostic recurring revenue organic growth: 12% (Q4, including 1% selling days benefit)VetLab consumable revenues organic growth: 12% (Q4)Overall instrument revenues organic decline: 12% (Q4)Rapid assay revenue organic growth: flat (Q4)Reference Lab revenues organic growth: 4% (Q4)Veterinary software services and diagnostic imaging revenues organic growth: 7% (Q4)
    		—6% organic——
    Water
    Water revenues increased organically in Q4, driven by continued solid gains in the U.S. and Europe.
    		—9% organic——
    LPD
    Livestock, poultry and dairy revenues increased organically in Q4, supported by solid gains in U.S., Europe and Latin America regions.
    		—7% organic——

    Operational metrics

    27
    CAG Diagnostic recurring revenue organic growth
    7%
    Q4 FY24

    Worldwide CAG Diagnostic recurring revenue increased organically in Q4.

    Global net price improvement
    4%-4.5%
    Q4 FY24

    Supported by average global net price improvement.

    U.S. net price realization
    3.5%
    Q4 FY24

    U.S. net price realization was approximately 3.5%.

    U.S. volume growth (normalized for equivalent days)
    2%
    Q4 FY24

    IDEXX execution drove approximately 2% U.S. volume growth in the quarter, normalized for equivalent days.

    U.S. same-store clinical visit decline
    3%
    Q4 FY24

    U.S. same-store clinical visit levels declined nearly 3% in Q4.

    U.S. same-store clinical visit decline
    2%
    FY24

    U.S. same-store clinical visit levels declined 2% for the full year in 2024.

    Global premium instrument installed base growth
    9%
    FY24

    9% growth in our global premium instrument installed base for the full year.

    Premium instrument placements
    18,500
    FY24

    Achieved approximately 18,500 premium instrument placements for the full year 2024.

    Premium instrument placements
    4,625down 12% from high prior year levels
    Q4 FY24

    Placed 4,625 premium instruments in the fourth quarter.

    IDEXX inVue Dx preorders
    1,600
    Q4 FY24

    Nearly 1,600 preorders globally for IDEXX inVue Dx by the end of Q4.

    Gross margin
    59.8%up 130 basis points
    Q4 FY24

    Gross margins were 59.8%, up 130 basis points on a comparable basis.

    Operating expenses growth
    10%
    Q4 FY24

    Operating expenses were up 10% as reported in the quarter.

    Operating expenses growth
    9%
    Q4 FY24

    Operating expenses were up 9% on a comparable basis in the quarter.

    Operating margin
    29%increase of 60 basis points
    FY24

    For the full year 2024, operating margins were 29%, an increase of 60 basis points on a comparable basis.

    EPS tax benefits from share-based compensation
    $0.13
    Q4 FY24

    EPS benefited from a lower effective tax rate, including $0.13 per share in tax benefits from share-based compensation activity.

    EPS nonrecurring tax reserve release benefit
    $0.06
    Q4 FY24

    EPS benefited from $0.06 per share benefit from a nonrecurring tax reserve release.

    EPS tax benefits from share-based compensation
    $0.24
    FY24

    2024 full year EPS results include $0.24 in tax benefits from share-based compensation activity.

    Free cash flow conversion
    91%
    FY24

    Free cash flow was 91% of net income for 2024.

    Capital spending
    $121M
    FY24

    Capital spending was $121 million for the full year or approximately 3% of revenue.

    Share repurchases
    $249M
    Q4 FY24

    Allocated $249 million to repurchase 564,000 shares in the fourth quarter.

    Share repurchases
    $859M
    FY24

    Allocated $859 million to repurchase 1,760,000 shares for the full year.

    Leverage ratio (gross)
    0.7x
    end of 2024

    Ended 2024 with leverage ratios of 0.7x gross.

    Leverage ratio (net of cash)
    0.4x
    end of 2024

    Ended 2024 with leverage ratios of 0.4x net of cash.

    Vello practices adopted
    600doubling its user base since Q3
    year-end

    Vello, our pet-owner engagement application, has been embraced by nearly 600 practices at year-end.

    Cloud native PIMS installed base growth
    20%
    YoY

    Placed a record number of cloud native PIMS, expanding that installed base by 20% year-over-year.

    Cloud native PIMS installed base in the cloud
    60%
    year-end

    Finished the year with 60% of our PIMS installed base in the cloud.

    IDEXX Web PACS subscriber growth
    double-digit
    Q4 FY24

    IDEXX Web PACS, our cloud native imaging workflow engine also experienced double-digit subscriber growth.

    Industry KPIs

    11
    MetricValueDetails
    Tariff impactpreliminary estimates
    System utilizationrelatively higher gains
    Pricing realized price4%-4.5%%
    New product launch ramp4,500-plusplacements
    Procedure volume growth800 basis pointbps
    FCF conversion leverage guidance91%%
    Installed base system placements18,500placements
    Segment franchise organic growth7%%
    Consumables recurring revenue mix12%%
    Sales force commercial capacity buildexpanded and trained
    Indicated addressable patient population$1.1 billionUSD

    Product announcements

    6
    ProductTypeDetails
    IDEXX inVue Dxlaunch
    IDEXX Cancer Dx with canine lymphomalaunch
    Pancreatic Lipase Testinglaunch
    SmartQClaunch
    IDEXX StatLab stationupdate
    Velloexpansion

    Deals & partnerships

    1
    3 major customersExtension and expansion of customer agreementslong-term

    Successful extension and expansion of 3 major customer agreements in 2024, which will provide long-term incremental volume growth benefits for IDEXX and benefit long-term Reference Lab growth for Reference Lab.

    Risks & headwinds

    5
    U.S. same-store clinical visit declinesQ4 2024 and full year 2024

    declined nearly 3% in Q4 and 2% for FY24

    Mitigation: IDEXX execution driving 800 bps growth premium; new innovations like Cancer Dx to inspire pull-through

    Macroeconomic conditions2025

    potential for further effects

    Mitigation: higher end of guidance captures potential improvement, lower end calibrates for further effects

    Tariff risks on internationally sourced materials2025

    preliminary estimates

    Mitigation: partially offsetting gross margin gains

    Foreign exchange impactQ4 2024, FY24, FY25

    $0.03 EPS headwind in Q4; $0.05 EPS headwind for FY24; $0.21 EPS headwind for FY25

    Mitigation: net of hedge gains

    Discrete litigation expense accrualQ2 2024

    $0.56 per share negative impact (FY24); 160 bps operating margin negative impact (FY24)

    Mitigation: lapping benefit in FY25

    What to watch in Q1 FY25

    5

    IDEXX inVue Dx placements

    Q1 2025 and throughout 2025
    CurrentInitial shipments in Q4 2024; ~1,600 preorders globally by end of Q4
    TargetProgress towards 4,500+ inVue placements in 2025

    Why it matters

    Verifies the ramp-up of a key new product launch and its contribution to instrument revenue and installed base growth.

    Underpinning the financial guidance Andrew shared is a placement target for 4,500-plus inVue placements over the course of the year as we march towards our 20,000 placement goal over 5 years.

    Q&A highlights

    6

    How much does innovation contribute to 2025 CAG recurring growth? Why are preorders for inVue Dx limited, and what's the status of FNA launch?

    Andrew stated $50M from 4,500 inVue Dx placements is included in guidance, with other innovations like PL and Cancer Dx also contributing. Jay explained the controlled launch process for inVue Dx to ensure customer experience, noting high customer interest (~1,600 preorders) and that customers are not waiting for FNA. FNA testing for lumps and bumps is expected later in 2025.

    “We plan to deliver the 4,500 plus inVue placements in 2025, as I indicated, that will ramp over the year.”

    asked by Erin Wilson Wright · answered by Andrew Emerson

    2 min read5 chapters

    Detailed Narrative

    01

    Innovation-Driven Growth

    IDEXX highlighted significant innovation in 2024, including the launch of IDEXX inVue Dx, a groundbreaking cellular analyzer, and IDEXX Cancer Dx for canine lymphoma. These new products, along with Catalyst menu extensions like Pancreatic Lipase Testing, are expected to drive future growth and enhance diagnostic utilization. The company is also expanding its software offerings to complement these innovations.

    02

    U.S. Clinical Visit Trends & IDEXX's Performance Premium

    The U.S. market continued to face headwinds with same-store clinical visits declining by nearly 3% in Q4 and 2% for the full year 2024. Despite this, IDEXX achieved an 800 basis point normalized growth premium over U.S. clinical visit growth in Q4, driven by solid new business gains, high customer retention, and increased diagnostic frequency per visit, particularly in wellness panels.

    03

    International Market Strength

    International CAG Diagnostic recurring revenue grew 12% in Q4, with Europe showing its seventh consecutive quarter of double-digit growth in CAG Diagnostics recurring revenue and high-teens growth in VetLab consumables. This strong performance is attributed to significant investments in commercial footprint over the past three years, leading to double-digit expansion of the premium instrument installed base outside the U.S.

    04

    Software and Digital Solutions

    The software business saw double-digit growth in cloud-native PIMS placements, expanding its installed base by 20% year-over-year, with 60% now in the cloud. The Vello pet owner engagement solution was adopted by nearly 600 practices, doubling its user base since Q3. These advancements aim to improve clinic efficiency, optimize workflows, and deepen connections with pet owners, reinforcing IDEXX's leadership in vertical SaaS for veterinarians.

    05

    CFO Transition

    Brian McKeon will retire after 11 years as CFO, with Andrew Emerson, previously SVP, Corporate and CAG Finance, assuming the role on March 1. Brian will remain with IDEXX in a senior advisory capacity until his retirement date of June 1 to ensure a smooth and seamless transition for Andrew, who brings over 20 years of finance experience to the role.

    AI-generated summary of the company’s earnings call. Not investment advice.